上海交通大学学报（医学版）

上海交通大学学报（医学版）

• 论著（基础研究） • 上一篇    下一篇

CD147在浸润性乳腺癌分子亚型中的表达与临床意义

叶辉1,徐明2,叶曼娜2,许杰莉2,汪成3   

  1. 上海市黄浦区中心医院 1.外科， 2.病理科， 3.乳腺外科， 上海 200002
  • 出版日期:2016-04-28 发布日期:2016-05-26
  • 通讯作者: 汪成, 电子信箱: wangcheng1212@hotmail.com。
  • 作者简介:叶辉（1969—）， 男， 副主任医师， 学士; 电子信箱: yehui1969@126.com。
  • 基金资助:

    上海市黄浦区科委基金（HKW201412）

Expression and clinical significance of CD147 in molecular subtypes of invasive breast cancer

Ye Hui1, Xu Ming2, Ye Man-na2, Xu Jie-li2, Wang Cheng3   

  1. 1.Department of Surgery, 2.Department of Pathology, 3.Department of Breast Surgery, The Central Hospital Huangpu District of Shanghai, Shanghai 200002, China
  • Online:2016-04-28 Published:2016-05-26
  • Supported by:

    Project of Science and Technology Commission of Huanghpu District in Shanghai, HKW201412

PDF (PC)

872

摘要：

目的 探讨浸润性乳腺癌分子亚型中CD147的表达及临床意义。 方法 收集251例浸润性乳腺癌患者的临床病理资料，并对各分子亚型进行CD147免疫组织化学检测。结果 CD147在浸润性乳腺癌中阳性表达率为64.10%（161/251），腔面 A亚型阳性表达率为29.30%（12/41），腔面 B亚型阳性表达率为50.00%（35/70），人表皮生长因子受体-2（HER2）阳性亚型阳性表达率为75.00%（42/56），三阴性（TNBC）亚型阳性表达率为85.70%（72/84）。在分子亚型中两两比较结果显示，HER2阳性亚型与TNBC亚型相比较差异无统计学意义（P=0.11），其余各亚型之间差异均有统计学意义（P=0.001）。在临床病理特征中CD147的高阳性表达率与高组织学分级、高临床分期、雌激素受体（ER）阴性及HER2阳性相关。结论 CD147在浸润性乳腺癌分子亚型中的表达与2013年第13届St Gallen国际乳腺癌会议共识相一致，即腔面 A亚型内分泌治疗敏感、惰性、预后较好，腔面B亚型内分泌治疗较差、侵袭性较强、预后较差及 ＜40岁女性患者中HER2亚型与TNBC亚型发病率相对较高，预后均较差。CD147抗体的研制有可能在浸润性乳腺癌TNBC亚型的个性化分子靶向治疗上有所帮助。

关键词: CD147, 浸润性乳腺癌, 分子亚型, 免疫组织化学, 预后

Abstract:

Objective To investigate the expression and clinical significance of CD147 in molecular subtypes of invasive breast cancer. Methods Clinical pathological data of 251 patients with invasive breast cancer were collected and immunohistochemical examination was performed for all molecular subtypes. Results The positive expression rates of CD147 in invasive breast cancer, luminal A subtype, luminal B subtype, human epidermal receptor 2 (HER2) positive subtype, and triple-negative (TNBC) subtype were 64.10% (161/251), 29.30% (12/41), 50.00% (35/70), 75.00% (42/56), and 85.70% (72/84), respectively. Comparison between subtypes showed that the difference between HER2 positive subtype and TNBC subtype was not statistically significant (P=0.11) and differences between other subtypes were statistically significant (P=0.001). High positive expression rate of CD147 was associated with clinicopathological characteristics such as high histological grade, high clinical stage, estrogen receptor (ER) negative and HER2 positive. Conclusion CD147 expression in molecular subtypes of invasive breast cancer is consistent with the consensus of 2013 the 13th St Gallen International Breast Cancer Conference, i.e. luminal A subtype is more endocrine sensitive, indolent, and better prognosis, while luminal B subtype is less endocrine sensitive, more aggressive, and worse prognosis, and TNBC subtype and HER2-positive subtype are more frequent in women under 40 years of age with poor prognosis. The development of CD147 antibodies may be helpful for individualized targeted treatment of TNBC subtype of invasive breast cancer.

Key words: CD147, invasive breast cancer, molecular subtype, immunohistochemistry, prognosis